



Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

BIO/SECL/SP/2024-25/80

August 30, 2024

To The Manager, BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code - 532523	To The Manager, National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 Scrip Symbol - Biocon
--	---

Dear Sir/ Madam,

Subject: Notification to Stock Exchanges

This is to inform you that Biocon Pharma Limited, a wholly owned subsidiary of the Company, has received approval of its ANDA for Daptomycin for injection (500mg vial), from the U.S Food and Drug Administration (US FDA). This product is indicated for use in the treatment of complicated skin and skin structure infections (cSSSI). It is also used to treat Staphylococcus aureus infections in the bloodstream (bacteremia), including right-sided infective endocarditis in adult patients.

The approval further adds to Biocon’s portfolio of complex drug products.

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

Mayank Verma
Company Secretary & Compliance Officer
Membership No. A18776